fda statement bpc-157 not approved for human use compounding FDA's Overreach on Compounded Peptides FDA considers adding a dozen
Description
Hes so knowledgeable and happily shares that knowledge, so its clear he knows what hes doing

However, it is now clear that this popular approach ignores the root causes of NAD+ decline meaning supplementation with precursors alone such as NR or NMN do not offer a long-term efficacious solution for NAD+ restoration

Previous studies have shown that TGF-3 can promote NPCs viability and stimulate aggrecan production (Reza and Nicoll, 2010

This patient underwent surgery and the multiple rounds of chemotherapy with oral and intravenous agents for 16 weeks, and no recurrence has been observed for the past 56 weeks
They have been shown to inhibit tumor activity and growth in multiple preclinical studies modeling a range of cancer types (Jokovi 2025

BPC-157 injury recovery peptide for tendon, ligament, muscle, angiogenesis, and collagen repair